BioPortUSA

BioPortUSA News and Event Updates

20 Apr

Teicos Pharma hires BioPortUSA

Teicos Pharma (www.teicospharma.com) is a Finish based Pharmaceutical Start-Up whose business is the production and sales of a new class of inhalable API (active pharmaceutical ingredient) powders for dry powder Inhalers (DPI). [...]

Read More
13 Apr

BioPortUSA starts work with Women Owned Fizimed

#

BioPortUSA announced today that they have started work with French based Fizimed “We are excited to be working with Fizimed, our first women founded and women owned life sciences client” said Mark Lesselroth, CEO of Bioport.[...]

Read More
01 Apr

BioPortUSA Adds New Board Member

BioPortUSA is excited to announce the addition of Dr. Karsten Risch to our Board of Advisors. Dr. Risch brings a unique skill set as Chief Medical officer for Evoke, a global life science marketing communications firm. [...]

Read More
30 Mar

New partnership with GloriMed Consulting

#

BioPortUSA announced a new partnership with GloriMed Consulting (http://www.glorimed.fr/), a leading French provider of Regulatory Affairs, Development, Marketing and communications for the medical device industry.[...]

Read More
24 Jan

Alliance Partner GlobalMedHub

BioPortUSA announced a new partnership with GlobalMedHub a leading Middle East medtech consultancy based out of Dubai. GMH is strategically positioned to help international medtech companies from Europe and the U.S.A. to gain access to a challenging market.[...]

Read More
16 Dec

Medical Device Academy and FDA Attorney join BioPortUSA

BioPortUSA is pleased to announce the addition of two more subject matter experts to our team. Medical Device Academy is considered to be one of the top boutique FDA consultancies that also has a firm understanding of regulatory requirements from other countries around the world including CE and MDR marking. Mark Lesselroth, CEO of BioPortUSA said that “we are thrilled to have Rob Pakcard and his team on board not only because they can assist our international med-tech companies with 510K and De Novo applications but also because they have the ability to help our U.S. based clients with navigating the regulatory pathway in other parts of the world.”[...]

Read More